PHILADELPHIA, May 06, 2025--iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase ...

The OTC-HOPE study is a Phase 1/2 first-in-human clinical trial of ECUR-506 in baby boys with genetically confirmed neonatal onset OTC deficiency and has been cleared to evaluate ascending dose ...

ASGCT Details: Poster Title: Initial clinical results from OTC-HOPE, the first in vivo, liver directed, AAV-mediated gene insertion study in neonatal OTC deficiency: complete clinical response ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor ...

For DTX301 in ornithine transcarbamylase deficiency, or OTC, the Phase 3 study completed enrollment in the first quarter is on track to read out data over the next year. For UX701 Wilson disease, the ...

For DTX301 and ornithine transcarbamylase deficiency or OTC. The Phase 3 study completed enrollment in the first quarter, and is on track to read out data over the next year. For UX701 and Wilson ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.